Enliven Therapeutics, Inc. (ELVN)

Real-time intraday values

Market Overview

From:

To:

ELVN Intraday

No data available

SymbolELVN

IPO DateMar 12, 2020

CEOMr. Richard A. Fair M.B.A.

Full Time Employees61

SectorHealthcare

IndustryBiotechnology

CountryUnited States

ExchangeNasdaqGS

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Performance

Period	Return %	Value Change
1 Day	+11.27%	+4.17 US$
5 Days	+18.61%	+6.46 US$
1 Month	-2.67%	-1.13 US$
6 Months	+144.19%	+24.31 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of ELVN...

Key Statistics

Market Cap

2.51B

P/E Ratio

N/A

Div Yield

N/A

52W High

$48.53

52W Low

$14.79

Analyst Consensus

ConsensusStrong Buy

Bullish10100.0%

Neutral00.0%

Bearish00.0%

52W Analyst Price Targets

Min Target
$45.00

Max Target
$80.00

Current$41.17

Avg Target$59.22

Analyst Recommendations

Target Price:$59.22($45.00 - $80.00)

Firm	Rating	Target Price	Upside Potential	Date
Stifel	Buy	$60.00	+45.74%	6/9/2026
Mizuho	Outperform	$62.00	+50.60%	6/2/2026
Goldman Sachs	Buy	$59.00	+43.31%	5/8/2026
HC Wainwright & Co.	Buy	$56.00	+36.02%	3/26/2026
Mizuho	Outperform	$45.00	+9.30%	3/25/2026